| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-083 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、可转债发行上市概况 经中国证券监督管理委员会《关于同意上海皓元医药股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可[2024]1289 号）同意，上海 皓元医药股份有限公司（以下简称"公司"、"本公司"）于 2024 年 11 月 28 日 向不特定对象发行 822.35 万张可转换公司债券，每张面值为人民币 100 元，发 行总额 82,235.00 万元，期限 6 年。 经上海证券交易所自律监管决定书[2024]168 号文同意，公司本次可转换公 司债券于 2024 年 12 月 19 日起在上海证券交易所上市交易，债券简称"皓元转 债"，债券代码"118051"。 根据有关规定和公司《向不特定 ...

本次股票上市流通总数为648,570股。 | 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-081 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于 2022 年限制性股票激励计划首次授予部分 第三个归属期以及预留部分第二个归属期归属结果暨 股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 648,570股，占归属前公司股本总额的 0.31%。 本次股票上市流通日期为2025 年 7 月 8 日。 根据中国证监会、上海证券交易所、中国证券登记结算有限责任公司上海分 公司有关业务规则的规定，公司 2022 年限制性股票激励计划首次授予部分第三个 归属期以及预留部分第二个归属期于 2025 年 6 月 30 日完成归属登记手续，已收 到中国证券登记结算有限责任公司上海分公司出具的《证券变更登记证明》。现将 有关情况公告如下： ...

Group 1 - Shida Shenghua expects a net loss of 52 million to 60 million yuan for the first half of 2025, a year-on-year decrease of 236.64% to 257.66% [1] - ST Zhizhi's vice president Wang Dong resigned for personal reasons, effective immediately upon delivery of the resignation to the board [1] - Haoyuan Pharmaceutical plans to increase capital by 400 million yuan to its wholly-owned subsidiary through a debt-to-equity swap, raising the registered capital from 400 million to 800 million yuan [1] Group 2 - Longxun Co. announced that shareholders and executives plan to reduce their holdings by up to 2% of the company's shares [2] - Aijian Group confirmed it has not engaged in any stablecoin-related business as of now [3] - Yanghe Co.'s chairman Zhang Liandong resigned due to work adjustments, effective immediately [5] Group 3 - Huanwei New Materials announced a stock suspension due to the major matter that may lead to a change in control [5] - Hualing Cable recently won contracts worth 456 million yuan in the power new energy sector, accounting for 10.97% of its audited revenue for 2024 [6] - Aerospace Changfeng plans to publicly transfer 55.45% of its stake in Aerospace Boke [6] Group 4 - Suzhou Planning is planning to acquire control of Dongjin Aerospace Technology, leading to a stock suspension for up to 10 trading days [6] - Yuexiu Capital intends to increase its stake in Yuexiu Real Estate using up to 204.22 million yuan through the Hong Kong Stock Connect [6] - Baichuan Co.'s actual controller and chairman Zheng Tiejiang is under investigation and has received a detention notice [7] Group 5 - XWANDA plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [8] - ST Aowei reported a loss of approximately 25.04 million yuan in inventory due to poor storage by a third party [8] - Yian Technology plans to increase capital by 120 million yuan to its subsidiary, raising its equity stake from 60% to 72.973% [9] Group 6 - Dongli New Science's wholly-owned subsidiary was applied for bankruptcy reorganization by creditors due to insolvency [11] - Bochuang Technology changed its name to Changxin Bochuang Technology, effective July 2, 2025 [14] - Huayang Co.'s controlling shareholder received a notice of administrative penalty from the China Securities Regulatory Commission [15] Group 7 - Hangzhou Thermal Power's shareholders plan to reduce their holdings by up to 4.09% of the company's shares [16] - Guoke Military Industry's two shareholders plan to reduce their holdings by up to 1.81% of the company's shares [17] - Pangu Intelligent's seven shareholders plan to reduce their holdings by up to 1% of the company's shares [19]

Core Viewpoint - The company plans to increase its capital in its wholly-owned subsidiary, Anhui Haoyuan Pharmaceutical Co., Ltd., through a debt-to-equity conversion to alleviate financial pressure and optimize its capital structure [4][6][7]. Summary by Sections 1. Basic Situation of the Capital Increase - The company has formed a fundraising debt of RMB 40 million from Anhui Haoyuan due to the completion of the "Anhui Haoyuan Biological Pharmaceutical R&D Center Construction Project" in 2021 [1]. - For the "Anhui Haoyuan Annual Production of 121.095 Tons of Pharmaceutical Raw Materials and Intermediates Construction Project (Phase I)," the company has a fundraising debt of RMB 527.26 million and a self-funding debt of RMB 164.53 million [2]. 2. Approval Process - The company’s board of directors approved the use of RMB 180 million of raised funds for capital increase on July 12, 2021, and later approved a debt-to-equity conversion of RMB 200 million on March 22, 2024 [3][4]. 3. Purpose and Impact of the Capital Increase - The capital increase aims to relieve Anhui Haoyuan's financial pressure, optimize its asset-liability structure, and enhance its competitive strength [6][7]. - After the capital increase, Anhui Haoyuan's registered capital will rise from RMB 400 million to RMB 800 million, and it will remain a wholly-owned subsidiary of the company [4][7]. 4. Financial Situation of Anhui Haoyuan - As of the end of the first quarter of 2024, Anhui Haoyuan's total assets were RMB 797.34 million, total liabilities were RMB 584.89 million, and net profit was -RMB 113.37 million [6]. 5. Opinions from the Board and Supervisory Committee - The board and supervisory committee agree that the debt-to-equity conversion will not harm the interests of the company or its shareholders, particularly minority shareholders [7][8].

Core Viewpoint - The Shanghai Haoyuan Pharmaceutical Co., Ltd. is holding its fourth extraordinary general meeting of shareholders in 2025 to discuss significant governance changes, including the cancellation of the supervisory board and amendments to the company's articles of association [6][7]. Group 1: Meeting Procedures - The meeting will verify the identity of attendees and restrict entry to authorized personnel only [2]. - Shareholders must arrive 30 minutes prior to the meeting for registration and must present valid identification [2]. - Attendees are required to maintain order during the meeting and adhere to the established rules for speaking and voting [3][5]. Group 2: Agenda Items - The meeting will address two main proposals: the cancellation of the supervisory board and the revision of the company's articles of association [6][7]. - The second proposal includes 13 sub-proposals aimed at improving corporate governance and operational efficiency [8]. Group 3: Voting and Decision-Making - Voting will be conducted through a combination of on-site and online methods, with specific time slots designated for each [5][6]. - The results of the voting will be announced by the meeting host after the counting process is completed [5][6]. Group 4: Governance Changes - The proposal to cancel the supervisory board is based on recent legal amendments and aims to enhance the board's oversight capabilities through the audit committee [7]. - The company plans to revise its governance structure in accordance with the new legal framework and operational needs [8][9].

Major Events - Newland has established a subsidiary in the US and obtained an MSB license to enhance its global payment business and facilitate cross-border payment operations [3] - Zhejiang Liming's actual controllers have committed not to reduce their shareholdings within one year [4] - Tengya Precision has announced a three-month commitment from its major shareholders not to reduce their holdings [6] - *ST Yuancheng is under investigation by the CSRC for suspected false financial disclosures [7] - Anglikang has only one innovative drug project currently under development, which is in the I phase of clinical trials [8] - Yongmaotai plans to invest approximately 450 million yuan to build an intelligent manufacturing base for auto parts in Mexico [9] - Fengfan Co. intends to acquire 100% equity of eight photovoltaic power station project companies for 48 million yuan [10] - Hangzhou High-tech is changing its controlling shareholder to Jirong Weiye and will resume trading on July 2 [11][12] - Zhongke Environmental Protection is acquiring 100% equity of two environmental companies for a total of 354 million yuan [13] - Yian Technology plans to increase its investment in its subsidiary Yihang Metal by 120 million yuan [14] - *ST Aowei has reported asset losses due to mismanagement by a processing partner [15] - XWANDA intends to issue H-shares and list on the Hong Kong Stock Exchange [16] - Baichuan Co.'s actual controller and chairman is under investigation [17] - Suzhou Planning is planning to acquire control of Dongjin Aviation Technology and will suspend trading [19] - Aerospace Changfeng plans to transfer 55.45% equity of a subsidiary through public listing [20] Performance Overview - Xinhecheng expects a net profit increase of 50%-70% for the first half of 2025, estimating between 3.3 billion to 3.75 billion yuan [21] - Shida Shenghua anticipates a net loss of 52 million to 60 million yuan for the first half of 2025 [22] - Kids' King expects a net profit increase of 50%-100% for the first half of 2025, estimating between 120 million to 160 million yuan [23] - SAIC Group reported a total vehicle sales of 2.0526 million units in the first half of 2025, a year-on-year increase of 12.35% [24] - BAIC Blue Valley's subsidiary reported a 139.73% increase in sales for the first half of 2025 [25] - Seris reported a 4.44% year-on-year increase in electric vehicle sales for June [26] - Great Wall Motors reported a 1.81% increase in total vehicle sales for the first half of 2025 [27] Major Contracts - Guoxin Technology has won a 46 million yuan project for automotive electronic chips [28] - Ankao Zhidian has signed two contracts for wind power transmission projects totaling 79.69 million yuan [29] Shareholding Changes - Wuxi Zhenhua's shareholder plans to reduce its stake by up to 1% [30] - Longxun Co. shareholders plan to reduce their holdings by up to 2% [31] - FJ Environmental's major shareholder plans to reduce its stake by up to 3% [32] - Yuexiu Capital's subsidiary plans to increase its stake in Yuexiu Real Estate [33] Financing Activities - Haoyuan Pharmaceutical plans to increase its subsidiary's capital by 400 million yuan through debt-to-equity conversion [34] - Hainan Huatie plans to issue bonds not exceeding 2 billion yuan to optimize its financing structure [35]

民生证券股份有限公司 关于上海皓元医药股份有限公司 以债转股方式向全资子公司增资的核查意见 因公司实施"安徽皓元年产 121.095 吨医药原料药及中间体建设项目（一 期）"，安徽皓元作为募投项目实施主体向公司募集资金专户及自有资金账户请款， 安徽皓元收到公司支付的相应款项后，根据签署的合同及项目进度及时向供应商 完成支付，该项目已于 2024 年结项。公司在该项目中形成对安徽皓元的募集资 金债权为人民币 52,726.14 万元，自有资金债权为人民币 16,453.49 万元。 公司于 2021 年 7 月 12 日分别召开了第二届董事会第十九次会议、第二届监 事会第九次会议，审议通过了《关于使用募集资金向全资子公司增资以实施募投 项目的议案》，同意公司使用募集资金 18,000 万元向安徽皓元增资以实施募投项 目的建设事项；公司于 2024 年 3 月 22 日分别召开了第三届董事会第三十四次会 1 议、第三届监事会第三十二次会议，审议通过了《关于以债转股方式对全资子公 司增资的议案》，同意公司以债转股方式向安徽皓元增资人民币 20,000.00 万元。 具体内容详见公司分别于 2021 年 7 月 14 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-080 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 增资标的名称：安徽皓元药业有限公司（以下简称"安徽皓元"） 增资方式及金额：上海皓元医药股份有限公司（以下简称"公司"或"皓 元医药"）以债转股方式向全资子公司安徽皓元增资 40,000.00 万元人民币（以下 简称"本次增资"）。其中，由公司首次公开发行股票募集资金形成的债权 18,726.14 万元，由公司自有资金形成的债权 21,273.86 万元。 相关风险提示：本次增资属于公司董事会决策权限范围事项，无需提交 公司股东大会审议批准。本次增资事项不构成关联交易，亦不构成《上市公司重 大资产重组管理办法》规定的重大资产重组，不会对公司的财务状况和未来经营 成果造成重大不利影响。 公司于 2025 年 6 月 30 日召开第四届董事会第七次会议、第四届监事会第七 次会议， ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-079 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 第四届监事会第七次会议决议公告 1 告编号：2025-080）。 特此公告。 二、监事会会议审议情况 与会监事以记名投票表决方式审议并通过了：《关于以债转股方式对全资 子公司增资的议案》 公司本次以债权转股权方式向全资子公司安徽皓元药业有限公司（以下简称 "安徽皓元"）增资，不存在损害公司及股东利益的情形，相关决策审批程序符 合相关法律法规的规定。本次增资完成后安徽皓元的注册资本增加至人民币 80,000.00 万元，仍为公司全资子公司。因此，监事会同意公司以债转股方式向 安徽皓元增资。 表决结果：3 名赞成，占全体监事人数的 100%；0 名弃权，0 名反对。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《上海皓元医药股份有限公司关于以债转股方式对全资子公司增资的公告》（公 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对 ...

上海皓元医药股份有限公司 2025年第四次临时股东大会会议资料 转债代码：118051 转债简称：皓元转债 证券代码：688131 证券简称：皓元医药 2025年第四次临时股东大会会议资料 二〇二五年七月 上海皓元医药股份有限公司 2025年第四次临时股东大会会议资料 2025年第四次临时股东大会会议资料 上海皓元医药股份有限公司 目 录 | 上海皓元医药股份有限公司2025年第四次临时股东大会会议须知 | 3 | | --- | --- | | 上海皓元医药股份有限公司2025年第四次临时股东大会会议议程 | 5 | | 上海皓元医药股份有限公司2025年第四次临时股东大会会议议案 | 7 | | 议案一：关于取消监事会并修订《公司章程》的议案 | 7 | | 议案二：关于修订、制定及废止公司部分治理制度的议案 | 8 | 2 2025年第四次临时股东大会会议须知 为维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会的 顺利进行，依据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民 共和国证券法》（以下简称"《证券法》"）《上市公司股东会规则》及《上海皓元 医药股份有限公司章程》 ...